Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Will Physician Demand For Repatha Put Pressure On Payer Restrictions?

Executive Summary

FOURIER outcomes data presented at the American College of Cardiology annual meeting fell short of expectations, but could increase physician demand for the PCSK9 inhibitor, making it harder for payers to say no.


Related Content

Repatha Pricing Pressure Might Actually Increase After Outcomes Trial
Amgen's Repatha Contract With Harvard Pilgrim Includes A Full Refund
Few Clouds On High-Priced, Ultra-Orphan Drug Horizon
Amgen Says Repatha Outcomes Trial Backs Up Its Pricing Math
PCSK9 Inhibitors' First Birthday Brings Sluggish Sales And More Bad Press
Scoring Value: New Tools Challenge Pharma's US Pricing Bonanza


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts